iRadimed
IRMD
39 hedge funds and large institutions have $29.8M invested in iRadimed in 2015 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 3 closing their positions.
600% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 3
86% more funds holding
Funds holding: 21 → 39 (+18)
50% more capital invested
Capital invested by funds: $19.8M → $29.8M (+$9.98M)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
Top Sellers
| 1 |
SC
Sophrosyne Capital
New York
|
-$4.94M |
| 2 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$918K |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$577K |
| 4 |
Goldman Sachs
New York
|
-$51.5K |
| 5 |
OAM
Oberweis Asset Management
Lisle,
Illinois
|
-$36.5K |
IRMD Hedge Fund Activity: Q2 2015 in Review
39 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in iRadimed (IRMD) for Q2 2015, worth a combined $29.8M — up 50% from $19.8M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new IRMD positions and 3 closed out — a net gain of 18 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was EAM Investors, opening a new position worth an estimated $1.43M. The largest seller was Sophrosyne Capital, cutting an estimated $4.94M.
- 39 institutional investors held iRadimed (IRMD) as of Q2 2015, up from 21 in Q1 2015.
- Funds reported $29.8M of iRadimed stock for Q2 2015, up 50% quarter-over-quarter.
- 21 funds opened new iRadimed positions in Q2 2015 and 3 closed out, a net change of +18 holders.
- The largest iRadimed buyer in Q2 2015 was EAM Investors, an estimated $1.43M added.
- The largest iRadimed seller in Q2 2015 was Sophrosyne Capital, an estimated $4.94M sold.
Based on aggregated 13F filings for Q2 2015.